 |
9 Diseases |  |
4 Trials |
|
4 Trials |  |
90 News |  |
| «12 |
- CHF6001 / Chiesi
Efficacy and safety of four doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i), in patients with moderate-to-severe COPD (6F) - Aug 26, 2019 - Abstract #ERS2019ERS_286;
CHF6001 add-on to maintenance bronchodilator in moderate-to-severe COPD patients reduced the rate of moderate and severe exacerbations vs placebo after 24-weeks treatment Figure. Moderate and severe COPD exacerbation rate ratio vs. Placebo in different populations
- |||| tanimilast (CHF6001) / Chiesi
Trial completion: Pharmacodynamics, Pharmacokinetics and Safety of Two Doses of CHF6001 DPI in Subjects With Moderate, Severe COPD (clinicaltrials.gov) - Jan 18, 2018
P2, N=61, Completed, Sponsor: Chiesi Farmaceutici S.p.A.
Moderate and severe COPD exacerbation rate ratio vs. Placebo in different populations Recruiting --> Completed
- |||| tanimilast (CHF6001) / Chiesi
Trial completion: PIONEER: A 24-wk Dose Ranging Study to Evaluate the Efficacy and Safety of 4 Doses of a New PDE4 Inhibitor in Patients With COPD (clinicaltrials.gov) - Jan 10, 2018
P2, N=1130, Completed, Sponsor: Chiesi Farmaceutici S.p.A.
Recruiting --> Completed Active, not recruiting --> Completed
- ||| tanimilast (CHF6001) / Chiesi
Enrollment closed: PIONEER: A 24-wk Dose Ranging Study to Evaluate the Efficacy and Safety of 4 Doses of a New PDE4 Inhibitor in Patients With COPD (clinicaltrials.gov) - Nov 22, 2017
P2, N=1130, Active, not recruiting, Sponsor: Chiesi Farmaceutici S.p.A.
Active, not recruiting --> Completed Not yet recruiting --> Active, not recruiting
- ||||| tanimilast (CHF6001) / Chiesi
New P2 trial: Pharmacodynamics, Pharmacokinetics and Safety of Two Doses of CHF6001 DPI in Subjects With Moderate, Severe COPD (clinicaltrials.gov) - Dec 28, 2016
P2, N=60, Recruiting, Sponsor: Chiesi Farmaceutici S.p.A.
- ||||| tanimilast (CHF6001) / Chiesi
New P2 trial: PIONEER: A 24-wk Dose Ranging Study to Evaluate the Efficacy and Safety of 4 Doses of a New PDE4 Inhibitor in Patients With COPD (clinicaltrials.gov) - Dec 8, 2016
P2, N=1102, Not yet recruiting, Sponsor: Chiesi Farmaceutici S.p.A.
- | tanimilast (CHF6001) / Chiesi
Trial completion: CHF6001Ext: A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF6001 (clinicaltrials.gov) - Oct 31, 2016
P1, N=48, Completed, Sponsor: Chiesi Farmaceutici S.p.A.
Not yet recruiting --> Active, not recruiting Recruiting --> Completed
- | tanimilast (CHF6001) / Chiesi
New P1 trial: CHF6001Ext: A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF6001 (clinicaltrials.gov) - Mar 12, 2015
P1, N=48, Recruiting, Sponsor: Chiesi Farmaceutici S.p.A.
- |||| tanimilast (CHF6001) / Chiesi
Trial completion: Safety, Tolerability and Efficacy of 28-day Inhaled CHF 6001 DPI in COPD Patients (clinicaltrials.gov) - Nov 19, 2014
P2, N=55, Completed, Sponsor: Chiesi Farmaceutici S.p.A.
Recruiting --> Completed Recruiting --> Completed
- | tanimilast (CHF6001) / Chiesi
Trial completion: Study to Investigate the Pharmacokinetics of CHF 6001 DPI Administered Via Nexthaler (clinicaltrials.gov) - Aug 1, 2014
P1, N=44, Completed, Sponsor: Chiesi Farmaceutici S.p.A.
Recruiting --> Completed Recruiting --> Completed
- | tanimilast (CHF6001) / Chiesi
New P1 trial: Study to Investigate the Pharmacokinetics of CHF 6001 DPI Administered Via Nexthaler (clinicaltrials.gov) - Apr 17, 2014
P1, N=48, Recruiting, Sponsor: Chiesi Farmaceutici S.p.A.
- | tanimilast (CHF6001) / Chiesi
Enrollment change: CHF6001_POC2: A Study to Evaluate the Efficacy After Allergen Challenge, Safety and Tolerability of Inhaled CHF6001 DPI in Asthmatics (clinicaltrials.gov) - May 7, 2013
P2, N=36, Completed, Sponsor: Chiesi Farmaceutici S.p.A.
Recruiting --> Completed N=30 --> 36
- | tanimilast (CHF6001) / Chiesi
Trial completion: CHF6001_POC2: A Study to Evaluate the Efficacy After Allergen Challenge, Safety and Tolerability of Inhaled CHF6001 DPI in Asthmatics (clinicaltrials.gov) - May 7, 2013
P2, N=36, Completed, Sponsor: Chiesi Farmaceutici S.p.A.
N=30 --> 36 Recruiting --> Completed
- ||||| tanimilast (CHF6001) / Chiesi
New P2 trial: Safety, Tolerability and Efficacy of 28-day Inhaled CHF 6001 DPI in COPD Patients (clinicaltrials.gov) - Nov 19, 2012
P2, N=65, Recruiting, Sponsor: Chiesi Farmaceutici S.p.A.
- ||| tanimilast (CHF6001) / Chiesi
New P1 trial: Safety and Tolerability of Inhaled CHF 6001 in Healthy Volunteers (HV) (clinicaltrials.gov) - Oct 8, 2012
P1, N=74, Completed, Sponsor: Chiesi Farmaceutici S.p.A.
- | tanimilast (CHF6001) / Chiesi
New P2 trial: CHF6001_POC2: A Study to Evaluate the Efficacy After Allergen Challenge, Safety and Tolerability of Inhaled CHF6001 DPI in Asthmatics (clinicaltrials.gov) - Sep 19, 2012
P2, N=36, Completed, Sponsor: Chiesi Farmaceutici S.p.A.